Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TOM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TOM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TOM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TOM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TOM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001094812 | Skin | cSCC | negative regulation of cell cycle process | 108/4864 | 294/18723 | 2.75e-05 | 3.09e-04 | 108 |
GO:004677715 | Skin | cSCC | protein autophosphorylation | 84/4864 | 227/18723 | 1.53e-04 | 1.35e-03 | 84 |
GO:00431624 | Skin | cSCC | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 14/4864 | 23/18723 | 4.32e-04 | 3.34e-03 | 14 |
GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
GO:004586025 | Skin | cSCC | positive regulation of protein kinase activity | 123/4864 | 386/18723 | 5.23e-03 | 2.64e-02 | 123 |
GO:003367426 | Thyroid | HT | positive regulation of kinase activity | 51/1272 | 467/18723 | 5.42e-04 | 6.46e-03 | 51 |
GO:001063925 | Thyroid | HT | negative regulation of organelle organization | 39/1272 | 348/18723 | 1.45e-03 | 1.36e-02 | 39 |
GO:004586020 | Thyroid | HT | positive regulation of protein kinase activity | 41/1272 | 386/18723 | 3.01e-03 | 2.43e-02 | 41 |
GO:000734618 | Thyroid | HT | regulation of mitotic cell cycle | 45/1272 | 457/18723 | 7.86e-03 | 4.61e-02 | 45 |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:0010639112 | Thyroid | PTC | negative regulation of organelle organization | 163/5968 | 348/18723 | 3.04e-09 | 8.39e-08 | 163 |
GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
GO:01400148 | Thyroid | PTC | mitotic nuclear division | 135/5968 | 287/18723 | 4.90e-08 | 1.04e-06 | 135 |
GO:004677716 | Thyroid | PTC | protein autophosphorylation | 110/5968 | 227/18723 | 1.25e-07 | 2.44e-06 | 110 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:00459307 | Thyroid | PTC | negative regulation of mitotic cell cycle | 105/5968 | 235/18723 | 2.41e-05 | 2.39e-04 | 105 |
GO:00319522 | Thyroid | PTC | regulation of protein autophosphorylation | 26/5968 | 43/18723 | 1.04e-04 | 8.42e-04 | 26 |
GO:00109486 | Thyroid | PTC | negative regulation of cell cycle process | 122/5968 | 294/18723 | 2.94e-04 | 2.08e-03 | 122 |
GO:00482855 | Thyroid | PTC | organelle fission | 188/5968 | 488/18723 | 9.64e-04 | 5.77e-03 | 188 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TOM1 | SNV | Missense_Mutation | rs201539247 | c.128N>T | p.Thr43Met | p.T43M | O60784 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
TOM1 | SNV | Missense_Mutation | novel | c.5N>G | p.Asp2Gly | p.D2G | O60784 | protein_coding | deleterious(0) | possibly_damaging(0.461) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
TOM1 | SNV | Missense_Mutation | | c.1163C>T | p.Ala388Val | p.A388V | O60784 | protein_coding | deleterious(0.01) | benign(0.234) | TCGA-EW-A1P8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD |
TOM1 | insertion | Frame_Shift_Ins | novel | c.566_567insAGGGAAG | p.Asp190GlyfsTer20 | p.D190Gfs*20 | O60784 | protein_coding | | | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TOM1 | insertion | Frame_Shift_Ins | novel | c.794_795insAAAATTAGCCAGGCGTGGTG | p.Gln266LysfsTer22 | p.Q266Kfs*22 | O60784 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOM1 | insertion | Frame_Shift_Ins | novel | c.1132_1133insGAGGGTACATTATGGTACTGTGGGCACCC | p.Ala378GlyfsTer17 | p.A378Gfs*17 | O60784 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOM1 | insertion | Nonsense_Mutation | novel | c.1123_1124insCTTCCCCAGCAGAATCAATGGATAGCGTTTTGACTGTTCTCTAAC | p.Ser375delinsThrSerProAlaGluSerMetAspSerValLeuThrValLeuTerArg | p.S375delinsTSPAESMDSVLTVL*R | O60784 | protein_coding | | | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TOM1 | SNV | Missense_Mutation | novel | c.784C>G | p.Arg262Gly | p.R262G | O60784 | protein_coding | deleterious(0) | possibly_damaging(0.551) | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TOM1 | SNV | Missense_Mutation | rs371088274 | c.505N>A | p.Val169Met | p.V169M | O60784 | protein_coding | deleterious(0.05) | possibly_damaging(0.872) | TCGA-EK-A2RL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | taxol | PD |
TOM1 | SNV | Missense_Mutation | rs371791801 | c.283N>A | p.Val95Met | p.V95M | O60784 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |